Skip to content
Search

Latest Stories

NHS to start world’s first 'artificial pancreas' trial, 100 years after discovery of insulin

Around 1,000 NHS patients with type 1 diabetes will take part in a trial of systems that continually monitor blood sugar levels and automatically adjust the amount of insulin given via a pump, according to a report in The Times.

Made by Medtronic, the device is the first hybrid closed-loop insulin delivery system to be approved anywhere in the world.


The pilot scheme will submit data to a national audit. Those results will feed into an assessment by the National Institute for Health and Care Excellence, which is considering whether NHS adoption of the technology would be “a clinically and cost-effective use of NHS resources”, the report said.

Patients taking part in the trial are expected to be those already using an insulin pump and wearing glucose monitors, but struggling to keep their blood sugar levels under control.

Experts hope that the new technology can prevent life-threatening hypoglycaemic attacks, as well as making patients’ lives easier by eliminating the need for finger prick tests, the report added.

“Living with diabetes is a daily challenge for millions of people, and this closed-loop technology has the potential to make a remarkable difference to their lives,” Sir Simon Stevens, chief executive of NHS England, told The Times.

“In a year that marks a century since insulin was discovered — which revolutionised the world of diabetes — this innovation is a prime example of the NHS’s continued progress in modern medicine and technology.”

People with type 1 diabetes — 8 per cent of people with diabetes in the UK — cannot produce enough insulin. They need daily doses of the hormone to keep blood sugar levels under control, delivered via an injector pen or a pump. Before the discovery of insulin in 1921 people with type 1 diabetes rarely lived more than a year or two.

Patients have traditionally taken regular blood sugar readings by pricking their fingers, although two fifths now use devices such as the Freestyle Libre, worn under the skin to monitor glucose levels.

They then inject insulin as needed. The new artificial pancreas goes further, with readings sent to a smart device that calculates how much insulin is needed and tells an insulin pump worn by the patient how much to release.

“One hundred years after the discovery of insulin, the artificial pancreas is a potentially revolutionary development in the treatment of diabetes,” Professor Partha Kar, the NHS national speciality adviser for diabetes, told The Times.

“The NHS has long been at the forefront of clinical advances in care for major diseases, including diabetes, which have allowed patients to live longer and healthier lives.”

More For You

Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less
Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less